Hear from the experts: LNPs driving the future of cell therapy

Ready to accelerate your cell therapy development?

Lipid nanoparticles (LNPs) are rapidly emerging as a versatile and scalable delivery platform for cell therapy applications - from transient mRNA expression to genome editing.

In this webinar, two leading experts, Dr. Sandy Tretbar (Fraunhofer IZI) and Dr. Friederike Herbst-Nowrouzi (University of Pennsylvania), share their latest research and translational insights into how LNPs are reshaping the future of cell therapy.

Dr. Sandy Tretbar (Fraunhofer IZI) presents on the development of mRNA-LNP technologies for engineering immune cells, highlighting their potential to improve safety, precision, and manufacturing flexibility. Dr. Friederike Herbst-Nowrouzi (University of Pennsylvania) showcases a novel two-component immunotherapy platform using base-edited CAR T cells and CD34⁺ HSPCs, enabled by LNP-mediated delivery of genome editing tools.

Watch this 45-minute session to explore how LNPs are unlocking new possibilities in cell therapy—from research to clinical translation.

To learn more about accelerating your cell therapy workflow with LNPs, or to get in touch with us about our end-to-end LNP-enabled cell therapy solutions, visit https://cytiva.link/tif9o.